Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07389941

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)

Status
Not Yet Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
240 (estimated)
Sponsor
University of Luebeck · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.

Conditions

Interventions

TypeNameDescription
DRUGSemaglutide (SEMA)Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)

Timeline

Start date
2026-10-01
Primary completion
2029-04-01
Completion
2029-04-01
First posted
2026-02-05
Last updated
2026-02-11

Source: ClinicalTrials.gov record NCT07389941. Inclusion in this directory is not an endorsement.